Efficacy and Safety of Dienogest for Endometriosis: A Systematic Review and Meta-Analysis of Standard-Dose Treatment With Supplementary Low-Dose Evidence

Systematic review / meta-analysis OA: green CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-11-16 ⓘ

This meta-analysis evaluated dienogest efficacy for endometriosis, finding 2 mg/d superior to placebo for pelvic pain with minimal bone mineral density loss and low discontinuation rates, while failing to confirm noninferiority of the 1 mg/d regimen.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This systematic review and meta-analysis evaluated the efficacy and safety of continuous dienogest (DNG) 2 mg/d for endometriosis, with supplementary evaluation of a low-dose 1 mg/d regimen. PubMed, Embase, and Web of Science were searched from database inception to October 27, 2026. Fifty-one study reports were included, of which 16 constituted the core outcome analysis set. Random-effects meta-analyses assessed lumbar spine bone mineral density (BMD) change and treatment discontinuation; pain outcomes were synthesized narratively. DNG 2 mg/d was superior to placebo for pelvic pain, with a pooled BMD change of −0.66% at approximately 24 weeks and pooled discontinuation proportions of 5.65% (adverse events) and 2.10% (bleeding). Noninferiority of DNG 1 mg/d was not confirmed.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-11-19T06:04:33.792782+00:00
License: CC0 · commercial use OK